Larimar Therapeutics (LRMR) Competitors

Kamada (NASDAQ:KMDA) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.

Which has better valuation & earnings, KMDA or LRMR?

Kamada has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$142.52M	2.37	$8.28M	$0.28	20.96
Larimar Therapeutics	N/A	N/A	-$36.95M	-$1.15	-5.36

Does the media refer more to KMDA or LRMR?

In the previous week, Larimar Therapeutics had 4 more articles in the media than Kamada. MarketBeat recorded 11 mentions for Larimar Therapeutics and 7 mentions for Kamada. Larimar Therapeutics' average media sentiment score of 0.69 beat Kamada's score of -0.43 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, KMDA or LRMR?

Kamada has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Is KMDA or LRMR more profitable?

Kamada has a net margin of 9.92% compared to Larimar Therapeutics' net margin of 0.00%. Kamada's return on equity of 6.30% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	9.92%	6.30%	4.49%
Larimar Therapeutics	N/A	-35.87%	-32.37%

Does the MarketBeat Community believe in KMDA or LRMR?

Kamada received 282 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 68.42% of users gave Larimar Therapeutics an outperform vote while only 65.91% of users gave Kamada an outperform vote.

Company	Underperform	Outperform
Kamada	Outperform Votes 321 65.91%	Underperform Votes 166 34.09%
Larimar Therapeutics	Outperform Votes 39 68.42%	Underperform Votes 18 31.58%

Do institutionals & insiders have more ownership in KMDA or LRMR?

20.4% of Kamada shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 3.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Do analysts recommend KMDA or LRMR?

Kamada currently has a consensus price target of $14.50, indicating a potential upside of 147.02%. Larimar Therapeutics has a consensus price target of $20.43, indicating a potential upside of 231.63%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Larimar Therapeutics	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09

Summary

Kamada beats Larimar Therapeutics on 10 of the 18 factors compared between the two stocks.